Jiuzhou Pharma Recognized in the 2026 Annual Collection of Listed Companies’ Sustainability Best Practices

Recently, Jiuzhou Pharma was selected for the 2026 Annual Collection of Listed Companies’ Sustainability Best Practices by the China Association for Public Companies (CAPCO). The Company’s submitted case study, titled “Driving Green Efficiency at Jiuzhou Pharma Through the 3E Model,” highlights its achievements in resource efficiency and circular economy practices.

2026-11-10

Jiuzhou Pharma Welcomes Yingzhou Xue as Its New President

2026-10-23

Jiuzhou Pharma Meets Customers and Partners at CPHI Milan 2026

2026-10-09

Nine Months. Eight Batches. Zero Deviations. How an Innovative Drug Program Cleared Critical Scale-Up Hurdles

2026-09-02

From Process Optimization to Registration Inspection: A Long-Term CDMO Collaboration in Practice

2026-08-19

How Advanced Small Molecule Synthesis is Accelerating Innovation

The pharmaceutical industry is undergoing a transformative shift, placing small molecule synthesis at the heart of next-generation drug discovery and development. As the demand for novel therapeutics intensifies, the ability to efficiently design, synthesize, and manufacture complex organic compounds is more critical than ever. Recent technological breakthroughs are redefining what is possible, moving small molecule synthesis from a traditional artisanal craft to a high-tech, data-driven process that promises to dramatically cut timelines and expand the boundaries of medicinal chemistry .

2026-08-11

From Complex Processes to Reliable Delivery: Solving API Development and Manufacturing Challenges for Innovative Medicines

2026-08-04

High-Purity Peptide Demand Surges as Next-Generation Therapeutics Drive Innovation in Pharmaceutical Manufacturing

The global pharmaceutical landscape is witnessing a paradigm shift, with high-purity peptide therapeutics emerging as a cornerstone for treating chronic diseases such as diabetes, obesity, and cancer. As the industry moves towards more targeted and potent therapies, the demand for superior-quality high-purity peptide active pharmaceutical ingredients (APIs) has intensified, putting a spotlight on advanced manufacturing capabilities and rigorous quality control.

2026-08-04

Advanced Peptide Synthesis Service Supports Innovation in Pharmaceutical and Biotechnology Research

With the rapid development of modern biotechnology, the demand for reliable and efficient peptide synthesis service solutions continues to grow across pharmaceutical, medical research, and life science industries. Researchers and companies increasingly rely on professional peptide production platforms to obtain high-quality peptides for drug discovery, diagnostic development, and customized biological studies.

2026-07-28

JiuZhou Pharma has been included in the FTSE4Good Index Series for the third consecutive year

2026-07-23

Haisco's Cipepofol Receives U.S. FDA Approval with CDMO Support from Jiuzhou Pharma

2026-07-21

Global Peptide Therapeutics Market Surges as CDMOs Invest in Specialized Peptide Drug Platform Capabilities

The pharmaceutical industry is witnessing a significant paradigm shift, with peptide therapeutics emerging as a powerful modality for treating a wide range of diseases. This growth is underscored by a wave of investment and strategic expansion in specialized peptide drug platform technologies. From AI-driven discovery to large-scale GMP manufacturing, the infrastructure for these complex molecules is rapidly maturing. In a strong vote of confidence for the sector, Syneron Bio recently secured a massive $150 million Series B financing round to advance its AI-driven peptide drug platform .

2026-07-21